Should anti-TNF-α drug levels and/or anti-drug antibodies be assayed in patients treated for rheumatoid arthritis?

Joint Bone Spine

Volumn 79, Issue 2, 2012, Pages 109-112

  Mulleman, Denis ^a,b   Ducourau, Emilie ^a,b   Paintaud, Gilles ^a   Ternant, David ^a,b   Watier, Hervé ^a,b   Goupille, Philippe ^a,b  

^a UNIVERSITÉ DE TOURS   (France)

^b UNIVERSITY HOSPITAL OF TOURS   (France)

Author keywords

Biopharmaceuticals; Immunogenicity; Monoclonal antibodies; Rheumatoid arthritis; Therapeutic drug monitoring

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

CLINICAL PRACTICE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDITORIAL; HUMAN; IMMUNOGENICITY; MEDICAL DECISION MAKING; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ANTAGONISM; DRUG TOLERANCE; DRUG TOXICITY; HUMANS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84857800242     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2011.11.004     Document Type: Editorial

References (20)

1. St Clair E.W., Wagner C.L., Fasanmade A.A., et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46:1451-1459.
2. Maini R.N., Breedveld F.C., Kalden J.R., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor-alpha monoclonal antibody combined with low dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998, 41:1552-1563.
3. Weisman M.H., Moreland L.W., Furst D.E., et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 2003, 25:1700-1721.
4. Keystone E.C., Schiff M.H., Kremer J.M., et al. Once-weekly administration of 50mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004, 50:353-363.
5. Wolbink G.J., Voskuyl A.E., Lems W.F., et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005, 64:704-707.
6. Bartelds G.M., Wijbrandts C.A., Nurmohamed M.T., et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007, 66:921-926.
7. Jamnitski A., Krieckaert C.L., Nurmohamed M.T., et al. Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Ann Rheum Dis 2011, 71:88-91.
8. Lee H., Kimko H.C., Rogge M., et al. Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther 2003, 73:348-365.
9. Rahman M.U., Strusberg I., Geusens P., et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis 2007, 66:1233-1238.
10. Mulleman D., Chu Miow Lin D., Ducourau E., et al. Trough infliximab concentrations predict efficacy and sustained control of disease activity in rheumatoid arthritis. Ther Drug Monit 2010, 32:232-236.
11. Wolbink G.J., Vis M., Lems W., et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:711-715.
12. Ternant D., Aubourg A., Magdelaine-Beuzelin C., et al. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit 2008, 30:523-529.
13. Xu Z., Seitz K., Fasanmade A., et al. Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. J Clin Pharmacol 2008, 48:681-695.
14. Bendtzen K., Geborek P., Svenson M., et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor-alpha inhibitor infliximab. Arthritis Rheum 2006, 54:3782-3789.
15. Ducourau E., Mulleman D., Paintaud G., et al. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther 2011, 13:R105.
16. Jamnitski A., Bartelds G.M., Nurmohamed M.T., et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis 2011, 70:284-288.
17. Bongartz T., Sutton A.J., Sweeting M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275-2285.
18. Baert F., Noman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348:601-608.
19. Cornillie F., Shealy D., D'Haens G., et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther 2001, 15:463-473.
20. Mulleman D., Meric J.C., Paintaud G., et al. Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis. Arthritis Res Ther 2009, 11:R178.